Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease

European Journal of Gastroenterology and Hepatology

Volumn 27, Issue 7, 2015, Pages 840-845

  Gangarapu, Venkatanarayana ^a   Ince, Ali Tüzün ^a   Baysal, Birol ^a   Kayar, Yusuf ^a   Kiliç, Ulkan ^a   Gök, Özlem ^a   Uysal, Ömer ^b   Şenturk, Hakan ^a  

^a ISTANBUL MEDIPOL UNIVERSITY   (Turkey)

^b BEZMIALEM VAKIF UNIVERSITY   (Turkey)

Author keywords

endotoxins; gut microbiota; lipopolysaccharides; nonalcoholic fatty liver disease; rifaximin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CYTOKINE; ENDOTOXIN; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; INSULIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; LIPID; RIFAXIMIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; RIFAMYCIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; FERRITIN BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; LIVER BIOPSY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX RATIO; ADOLESCENT; BIOPSY; BLOOD; COMPLICATION; DRUG EFFECTS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PREDICTIVE VALUE; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTI-INFECTIVE AGENTS; ASPARTATE AMINOTRANSFERASES; BIOMARKERS; BIOPSY; BODY MASS INDEX; CYTOKINES; DIABETES MELLITUS, TYPE 2; ENDOTOXINS; FEMALE; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RIFAMYCINS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84932147864     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000348     Document Type: Article

References (47)

1. Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2010; 26: 202-208
2. Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2011; 8: 35-44
3. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419
4. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-384
5. Hu KC, Wang HY, Liu SC, Liu CC, Hung CL, Bair MJ, et al. Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease. World J Gastroenterol 2014; 20: 7718-7729
6. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-1846
7. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004; 101: 15718-15723
8. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005; 102: 11070-11075
9. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-1031
10. Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012; 489: 242-249
11. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022-1023
12. Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013; 58: 120-127
13. Fernandes J, Su W, Rahat-Rozenbloom S, Wolever TM, Comelli EM. Adiposity, gut microbiota and faecal short chain fatty acids are linked in adult humans. Nutr Diabetes 2014; 4: e121
14. Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013; 11: 868-875
15. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-1772
16. Drenick EJ, Fisler J, Johnson D. Hepatic steatosis after intestinal bypass - prevention and reversal by metronidazole, irrespective of proteincalorie malnutrition. Gastroenterology 1982; 82: 535-548
17. Cameron RG, Neuman MG. Novel morphologic findings in alcoholic liver disease. Clin Biochem 1999; 32: 579-584
18. Crews FT, Bechara R, Brown LA, Guidot DM, Mandrekar P, Oak S, et al. Cytokines and alcohol. Alcohol Clin Exp Res 2006; 30: 720-730
19. Flamm SL. Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence. Therap Adv Gastroenterol 2011; 4: 199-206
20. Gillis JC, Brogden RN. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995; 49: 467-484
21. Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 2010; 26: 17-25
22. Bajaj JS, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, Stravitz RT, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 2013; 8: e60042
23. Kalambokis GN, Mouzaki A, Rodi M, Tsianos EV. Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia. Liver Int 2012; 32: 467-475
24. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321
25. Farhadi A, Gundlapalli S, Shaikh M, Frantzides C, Harrell L, Kwasny MM, Keshavarzian A. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int 2008; 28: 1026-1033
26. Thuy S, Ladurner R, Volynets V, Wagner S, Strahl S, Königsrainer A, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008; 138: 1452-1455
27. Bergheim I, Weber S, Vos M, Krämer S, Volynets V, Kaserouni S, et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 2008; 48: 983-992
28. Xu RY, Wan YP, Fang QY, Lu W, Cai W. Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. J Clin Biochem Nutr 2012; 50: 72-77
29. Vlachogiannakos J, Saveriadis AS, Viazis N, Theodoropoulos I, Foudoulis K, Manolakopoulos S, et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther 2009; 29: 992-999
30. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R. Changes in gut microbiota control metabolic endotoxemiainduced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57: 1470-1481
31. Medzhitov R, Horng T. Transcriptional control of the inflammatory response. Nat Rev Immunol 2009; 9: 692-703
32. Rivera CA, Adegboyega P, Van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007; 47: 571-579
33. Kanuri G, Ladurner R, Skibovskaya J, Spruss A, Königsrainer A, Bischoff SC, Bergheim I. Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease. Liver Int 2015; 35: 562-568
34. Wagnerberger S, Spruss A, Kanuri G, Volynets V, Stahl C, Bischoff SC, Bergheim I. Toll-like receptors 1-9 are elevated in livers with fructoseinduced hepatic steatosis. Br J Nutr 2012; 107: 1727-1738
35. Cobbold JF, Wai SN, Stove J, Shojaee-Moradie F, Fitzpatrick J, Thomas EL, et al. PTU-113 rifaximin in non-alcoholic steatohepatitis: an open-label pilot study. Gut 2013; 62: A92
36. Mandrekar P, Szabo G. Signalling pathways in alcohol-induced liver inflammation. J Hepatol 2009; 50: 1258-1266
37. Meli R, Mattace Raso G, Calignano A. Role of innate immune response in non-alcoholic fatty liver disease: metabolic complications and therapeutic tools. Front Immunol 2014; 5: 177
38. Van Exel E, Gussekloo J, De Craen AJ, Frölich M, Bootsma-Van Der Wiel A, Westendorp RG. Leiden 85 Plus Study. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes 2002; 51: 1088-1092
39. Esposito K, Pontillo A, Giugliano F, Giugliano G, Marfella R, Nicoletti G, Giugliano D. Association of low interleukin-10 levels with the metabolic syndrome in obese women. J Clin Endocrinol Metab 2003; 88: 1055-1058
40. Calcaterra V, De Amici M, Klersy C, Torre C, Brizzi V, Scaglia F, et al. Adiponectin, IL-10 and metabolic syndrome in obese children and adolescents. Acta Biomed 2009; 80: 117-123
41. Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, et al. Rifaximin improves driving simulator performance in randomized trial of patients with minimal hepatoencephalopathy. Gastroenterology 2011; 140: 478-487
42. Cintra DE, Pauli JR, Ara'jo EP, Moraes JC, De Souza CT, Milanski M, et al. Interleukin-10 is a protective factor against diet-induced insulin resistance in liver. J Hepatol 2008; 48: 628-637
43. Rosette C, Buendia-Laysa F Jr, Patkar S, Moro L, Celasco G, Bozzella R, et al. Anti-inflammatory and immunomodulatory activities of rifamycin SV. Int J Antimicrob Agents 2013; 42: 182-186
44. Jenkins DJ, Kendall CW, Hamidi M, Vidgen E, Faulkner D, Parker T, et al. Effect of antibiotics as cholesterol-lowering agents. Metabolism 2005; 54: 103-112
45. Angulo P, George J, Day CP, Vanni E, Russell L, De la Cruz AC, et al. Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014; 12: 1163.e1-1169.e1
46. Wrede CE, Buettner R, Bollheimer LC, Schölmerich J, Palitzsch KD, Hellerbrand C. Association between serum ferritin and the insulin resistance syndrome in a representative population. Eur J Endocrinol 2006; 154: 333-340
47. Kim CH, Kim HK, Bae SJ, Park JY, Lee KU. Association of elevated serum ferritin concentration with insulin resistance and impaired glucose metabolism in Korean men and women. Metabolism 2011; 60: 414-420